Why PYXS fell 24.5% on Sep 30 2026: registered offering

THE SESSION

• 09:30 ETOpened at $2.38, -18.1% on the previous close of $2.90
• 09:40 ETRegular-session high, $2.41
• 10:32 ETRegular-session low, $2.12
• 15:59 ETLast trade of the regular session, $2.33, -19.8% on the previous close of $2.90
• Volume: 6.0M shares in regular hours, 423K before the open

PYXS opened at $2.38, briefly reached $2.41, then fell to a $2.12 low by 10:32 ET before recovering to $2.33 at the regular-session close. TapeRank recorded the stock at rank #4 at 09:45 ET and found no halts; its read tied the decline to Pyxis Oncology pricing a $110 million registered equity offering at $2.90 with warrants for roughly 49.3 million additional shares, creating substantial dilution and share supply. The stock finished 19.8% below the previous close, after trading 18.1% lower at the open.

WRITTEN THU OCT 15 2026 17:59 ET BY OPENAI/GPT-5.6-LUNA FROM THE FACTS ON THIS PAGE

FILINGS AND NEWS · 24H BEFORE THE MOVE

• 02:56 ETPyxis Oncology Prices $110M Offering Of 36,047,919 Shares At $2.90 With Common Warrants For 49,310,352 Shares At $3.50 Exercise PriceBenzinga
• TUE 16:25 ETPyxis Oncology Launches Public Offering Of Common Stock/Pre-Funded Warrants And Warrants To Fund MICVO Phase 3 Development; No Terms DisclosedBenzinga
• TUE 16:24 ETPyxis Oncology Terminates $150M ATM Offering, Says As Of The Date Of This Supplement, We Have Not Sold Any Shares Of Our Common Stock Pursuant To The Sales AgreementBenzinga
• TUE 12:56 ET424B5 — Prospectus supplement — offering pricedSEC 424B5
• TUE 12:19 ET424B5 — Prospectus supplement — offering pricedSEC 424B5